Christine Pournaras, FNP-BC, brings over 36 years of nursing experience and a strong background in wellness, functional medicine, and metabolic health
The largest evidence to date comes from the Adjust-T1D trial, presented at this years American Diabetes Association Scientific Sessions
& Tan, D
But for a meaningful number of patients, the new oral GLP-1 pill is the right choice
However, despite no significant interaction, the benefits were lower among those with CKD stage 3 or higher.116 In the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54 (PEGASUS-TIMI 54) trial, adding ticagrelor to aspirin reduced the risk of recurrent ischemic events, including cardiovascular and coronary heart disease death in patients with DM and prior myocardial infarction, but the combination was also associated with a higher risk of TIMI major bleeding,117 and no subanalysis was performed on kidney function